Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.7150/ijms.53564

http://scihub22266oqcxt.onion/10.7150/ijms.53564
suck pdf from google scholar
33628091!7893562!33628091
unlimited free pdf from europmc33628091    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid33628091      Int+J+Med+Sci 2021 ; 18 (6): 1356-1362
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome #MMPMID33628091
  • Du P; Geng J; Wang F; Chen X; Huang Z; Wang Y
  • Int J Med Sci 2021[]; 18 (6): 1356-1362 PMID33628091show ga
  • Cytokine release syndrome (CRS) may be the key factor in the pathology of severe coronavirus disease 2019 (COVID-19). As a major driver in triggering CRS in patients with COVID-19, interleukin-6 (IL-6) appears to be a promising target for therapeutics. The results of inhibiting both trans- and classical- signaling with marketed IL-6 inhibitors (tocilizumab, siltuximab and sarilumab) in severe COVID-19 patients are effective based on several small studies and case reports thus far. In this review, we described the evidence of the IL-6 response in patients with COVID-19, clarified the pathogenesis of the role of IL-6-mediated CRS in severe COVID-19, and highlighted the rationale for the use of anti-IL-6 agents and key information regarding the potential features of these IL-6 inhibitors in COVID-19 patients.
  • |Antibodies, Monoclonal, Humanized/therapeutic use[MESH]
  • |Antibodies, Monoclonal/therapeutic use[MESH]
  • |COVID-19 Drug Treatment[MESH]
  • |COVID-19/*immunology/metabolism[MESH]
  • |Cytokine Release Syndrome/*drug therapy/*immunology/metabolism[MESH]
  • |Humans[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box